Immunovaccine Inc. is a clinical stage vaccine development company. The Company is focusing its research and development on developing an early stage human health vaccine pipeline consisting of infectious diseases and therapeutic cancer vaccine products. The Company�s advanced vaccine candidate is DPX-0907, a multivalent therapeutic cancer vaccine targeting ovarian, breast and prostate cancers. During the year ended December 31, 2010, the Company was in a multi-site Phase I human clinical trial for DPX-0907 in the United States. The Company has developed a lipid depot-based vaccine delivery and enhancement technology called the DepoVax platform, an improvement on the Company�s original VacciMax platform. The Company has completed proof of concept pre-clinical studies in infectious disease applications, such as single-dose DepoVax platform-based pandemic influenza and hepatitis B vaccine candidates.